Absci Corp (ABSI)
4.21
-0.04
(-0.94%)
USD |
NASDAQ |
May 31, 16:00
4.19
-0.02
(-0.48%)
After-Hours: 20:00
Absci SG&A Expense (Quarterly): 8.744M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.744M |
December 31, 2023 | 9.324M |
September 30, 2023 | 9.505M |
June 30, 2023 | 9.41M |
March 31, 2023 | 9.593M |
December 31, 2022 | 7.749M |
September 30, 2022 | 11.41M |
June 30, 2022 | 10.51M |
March 31, 2022 | 10.89M |
Date | Value |
---|---|
December 31, 2021 | 9.183M |
September 30, 2021 | 9.733M |
June 30, 2021 | 5.179M |
March 31, 2021 | 4.685M |
December 31, 2020 | 2.413M |
September 30, 2020 | 1.257M |
June 30, 2020 | 0.861M |
March 31, 2020 | 0.971M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.861M
Minimum
Jun 2020
11.41M
Maximum
Sep 2022
7.142M
Average
9.183M
Median
Dec 2021
SG&A Expense (Quarterly) Benchmarks
Eli Lilly and Co | 1.836B |
Creative Medical Technology Holdings Inc | 0.6715M |
CytomX Therapeutics Inc | 7.754M |
Bristol-Myers Squibb Co | 2.367B |
Recursion Pharmaceuticals Inc | 31.41M |